GlassScriptPhysician profile
Timothy S Shaver
NPI 1336145804
$39,392.99
in general payments reported to CMS, 2019-2025
41 companies · $6,481 in 2025
The $6,481 reported for 2025 was more than what 88% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $845 · 2021: $3,134 · 2022: $3,328 · 2023: $4,065 · 2024: $5,964 · 2025: $6,481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Consulting Fee: $910 · Education: $398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,202.36 |
| Consulting Fee | $910.00 |
| Education | $397.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $13,370.79 | 2019-2025 | |
| Amgen INC. | $5,077.63 | 2019-2025 | Evenity, Tavneos, Otezla |
| Abbvie INC. | $4,477.32 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Pfizer INC. | $2,170.27 | 2019-2025 | |
| Janssen Biotech, INC. | $1,897.83 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Ucb, INC. | $1,646.70 | 2019-2025 | Cimzia, Bimzelx |
| Mallinckrodt Hospital Products INC. | $1,335.26 | 2020-2025 | Acthar |
| Ani Pharmaceuticals, INC. | $1,125.10 | 2022-2025 | Purified Cortrophin Gel |
| Glaxosmithkline, LLC. | $1,026.43 | 2019-2025 | Benlysta, Nucala |
| Astrazeneca Pharmaceuticals LP | $909.25 | 2021-2025 | Saphnelo |
| Janssen Scientific Affairs, LLC | $682.56 | 2021-2025 | Tremfya |
| Horizon Therapeutics Plc | $624.49 | 2019-2023 | Krystexxa |
| Genentech USA, INC. | $564.98 | 2019-2025 | Actemra, Rituxan, Gazyva |
| Lilly USA, LLC | $560.72 | 2019-2024 | Taltz |
| Aurinia Pharma U.S., INC. | $539.53 | 2021-2024 | Lupkynis |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $487.79 | 2021-2025 | Ofev, Cyltezo |
| Alexion Pharmaceuticals, INC. | $419.11 | 2021-2025 | Strensiq |
| Sobi, INC | $396.56 | 2022-2025 | |
| Genzyme Corporation | $382.69 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $357.54 | 2019-2025 | Orencia |
| Radius Health, INC. | $298.60 | 2019-2025 | Tymlos |
| Gilead Sciences, INC. | $198.15 | 2019-2020 | |
| Genentech, INC. | $111.01 | 2025 | Gazyva |
| Regeneron Healthcare Solutions, INC. | $87.33 | 2019 | |
| Mallinckrodt Enterprises LLC | $82.33 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $81.02 | 2023-2024 | Takhzyro, Hyqvia |
| Tersera Therapeutics LLC | $79.87 | 2024-2025 | Quzyttir |
| Hospira, INC. | $58.42 | 2024-2025 | |
| Organon LLC | $52.90 | 2024-2025 | Hadlima, Renflexis |
| Zyla Life Sciences, INC. | $40.64 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $33.96 | 2021-2024 | Truxima |
| Actelion Pharmaceuticals US, INC. | $29.18 | 2019-2025 | Uptravi, Opsumit |
| Fresenius Kabi USA, LLC | $26.97 | 2023 | |
| Grifols USA, LLC | $25.00 | 2025 | Gamunex-C |
| Biocon Biologics INC | $24.99 | 2024 | Hulio |
| Octapharma USA, INC. | $23.55 | 2025 | Octagam Immune Globulin (Human) |
| Ultragenyx Pharmaceutical INC. | $22.42 | 2022 | |
| Mylan Institutional INC. | $20.28 | 2023 | Hulio |
| Antares Pharma, INC. | $15.00 | 2019 | |
| Celgene Corporation | $14.84 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Shaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.